Advertisement
U.S. markets closed

Astellas Pharma Inc. (ALPMF)

Other OTC - Other OTC Delayed Price. Currency in USD
11.160.00 (0.00%)
At close: 03:43PM EDT
  • Dividend

    ALPMF announced a cash dividend of 35.00 with an ex-date of Mar. 28, 2024

Advertisement
Show:
Annual
Upgrade to begin using 40 years of financial statements and get so much more.

Income Statement

Currency in JPY. All numbers in thousands
Upgrade to begin using 40 years of financial statements and get so much more.
Breakdown
ttm
3/31/2023
3/31/2022
3/31/2021
3/31/2020
Total Revenue
1,543,324,000
1,518,619,000
1,296,163,000
1,249,528,000
1,300,843,000
Cost of Revenue
281,536,000
288,353,000
253,009,000
246,063,000
276,739,000
Gross Profit
1,261,787,000
1,230,266,000
1,043,154,000
1,003,465,000
1,024,104,000
Operating Expense
1,245,086,000
1,098,709,000
912,191,000
867,892,000
778,452,000
Operating Income
16,701,000
131,557,000
130,963,000
135,573,000
245,652,000
Net Non Operating Interest Income Expense
-116,000
-669,000
1,200,000
9,273,000
1,359,000
Pretax Income
25,753,000
132,361,000
156,886,000
145,324,000
245,350,000
Tax Provision
21,556,000
33,647,000
32,800,000
24,734,000
49,939,000
Net Income Common Stockholders
4,198,000
98,714,000
124,086,000
120,589,000
195,411,000
Diluted NI Available to Com Stockholders
4,198,000
98,714,000
124,086,000
120,589,000
195,411,000
Basic EPS
19.03
54.24
67.08
64.93
104.15
Diluted EPS
18.84
54.09
67.05
64.90
104.08
Basic Average Shares
1,804,873
1,820,019
1,849,713
1,857,125
1,876,193
Diluted Average Shares
1,812,450
1,825,061
1,850,602
1,858,193
1,877,548
Total Operating Income as Reported
25,869,000
133,029,000
155,686,000
136,051,000
243,991,000
Total Expenses
1,526,622,000
1,387,062,000
1,165,200,000
1,113,955,000
1,055,191,000
Net Income from Continuing & Discontinued Operation
4,198,000
98,714,000
124,086,000
120,589,000
195,411,000
Normalized Income
-3,281,552
98,555,848
104,916,906
120,589,000
195,411,000
Interest Income
9,775,000
8,110,000
6,149,000
11,608,000
4,363,000
Interest Expense
9,891,000
8,779,000
4,949,000
2,335,000
3,004,000
Net Interest Income
-116,000
-669,000
1,200,000
9,273,000
1,359,000
EBIT
35,644,000
141,140,000
161,835,000
147,659,000
248,354,000
EBITDA
167,858,000
246,878,000
241,519,000
220,311,000
314,750,000
Reconciled Cost of Revenue
281,536,000
288,353,000
253,009,000
246,063,000
276,739,000
Reconciled Depreciation
132,214,000
105,738,000
79,684,000
72,652,000
66,396,000
Net Income from Continuing Operation Net Minority Interest
4,198,000
98,714,000
124,086,000
120,589,000
195,411,000
Total Unusual Items Excluding Goodwill
9,739,000
212,000
24,234,000
0
-
Total Unusual Items
9,739,000
212,000
24,234,000
0
-
Normalized EBITDA
158,119,000
246,666,000
217,285,000
220,311,000
314,750,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
2,259,448
53,848
5,064,906
0
0